Survival outcomes of Zo-NAnTAx: a five-year analysis of zoledronic acid added to a neoadjuvant regimen for HER2-positive breast cancer.

Bruno Henrique Rala de Paula Eliana AbdelhayCarlos Augusto Moreira de SousaSusanne Crocamo Ventilari da Costa

Published in: Annals of translational medicine (2024)

ZA plus neoadjuvant therapy in HER2-positive breast cancer shows provoking survival outcomes. Clinical and pre-clinical investigation with dual anti-HER2 blockage is warranted.

Keyphrases

positive breast cancer
rectal cancer
lymph node
locally advanced
stem cells
squamous cell carcinoma
radiation therapy
mesenchymal stem cells
cell therapy